AHRQ announces ARRA grant programs
This article was originally published in The Gray Sheet
Agency for Healthcare Research and Quality announces two HHS funding opportunities Sept. 25 for comparative effectiveness research supported through the American Recovery and Reinvestment Act of 2009 (1"The Gray Sheet" Aug. 10, 2009). Under the Clinical and Health Outcomes Initiative in Comparative Effectiveness (CHOICE) grants (RO1), AHRQ plans to provide up to a total of $100 million to up to 10 awardees. For the Innovative Adaptation and Dissemination of AHRQ Comparative Effectiveness Research Products (iADAPT) grants (R18), AHRQ plans to distribute $29.5 million among 20 to 25 awardees. The CHOICE program seeks applications for research aimed at generating new knowledge to help inform decision-making in priority areas of clinical care, while the iADAPT program looks for new ways to adapt content and delivery mechanisms of the agency's comparative effectiveness research summary guides, especially for underserved patient and consumer populations. Applications are due Dec. 16
You may also be interested in...
Two Health and Human Services agencies will allocate about $250 million this year in comparative effectiveness research funds from the federal stimulus package; the remainder of the $1.1 billion comparative effectiveness money will be put to use in 2010
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.